ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.
한글목차
키메라 항원 수용체-자연살해 세포(CAR-NK) 세포 치료 시장 규모는 최근 현저한 성장을 이루고 있습니다. 2025년 24억 2,000만 달러에서 2026년에는 25억 8,000만 달러로, CAGR 6.6%로 확대될 전망입니다. 지난 수년간의 성장 요인으로는 CAR-NK 치료제의 공급 제한, 자가 NK세포 치료제에 대한 의존도, 혈액암 발생률 증가, 종양학 연구 활동의 활성화, 초기 세대 NK세포 치료제의 규제 승인 등을 꼽을 수 있습니다.
키메라 항원 수용체-자연살해(CAR-NK) 세포 치료 시장 규모는 향후 몇 년간 강력한 성장이 전망됩니다. 2030년에는 32억 8,000만 달러에 달하고, CAGR은 6.2%를 기록할 전망입니다. 예측 기간의 성장 요인으로는 유전자 변형 CAR-NK 세포 개발, 기성 치료제 확대, 사이토카인 및 T 세포 수용체 변형 NK 세포의 채택 증가, 임상시험에 대한 자금 투입 확대, 치료 최적화를 위한 AI와 빅데이터의 통합 등을 꼽을 수 있습니다. 예측 기간 동안 주요 동향으로는 동종(기성품) CAR-NK 세포 치료제의 성장, 혈액암 및 고형암에 대한 적용 확대, 유전자 편집 기술과 사이토카인 유전자 변형 기술의 통합, 병용요법 및 면역관문억제제 도입 증가, 임상시험 및 종양학 연구 프로그램에 대한 투자 증가 등이 있습니다. 대한 투자 증가를 들 수 있습니다.
전 세계적으로 암 발생률이 증가함에 따라 향후 몇 년간 키메라 항원 수용체-자연살해(CAR-NK) 세포 치료 시장의 성장을 견인할 것으로 예상됩니다. 암은 비정상적인 세포의 통제할 수 없는 증식과 확산이 특징이며, 신체 조직에 침입 및 손상을 일으키는 질병군을 말합니다. 암 발생률의 증가는 고령화, 불건강한 생활습관 등의 요인에 기인합니다. 노화와 함께 시간이 지남에 따라 돌연변이가 축적되고 흡연, 부적절한 식습관, 운동 부족 등의 습관이 암 위험을 증가시키기 때문입니다. CAR-NK 세포 치료는 자연살해세포를 변형시켜 암세포를 특이적으로 인식하고 제거하도록함으로써 면역체계의 종양에 대한 표적 공격을 강화하여 암 치료를 돕습니다. 예를 들어, 2024년 2월 스위스에 본부를 둔 국제기구인 세계보건기구(WHO)는 2022년에 보고된 2,000만 건의 신규 암 사례가 2050년까지 77% 증가하여 3,500만 건을 넘어설 것으로 예측하고 있습니다. 따라서 전 세계 암 발생률의 증가는 CAR-NK 세포 치료 시장의 성장을 촉진하고 있습니다.
CAR-NK 세포 치료 시장의 주요 기업들은 보다 안전하고 효과적인 기성품 세포 치료제를 개발하기 위해 전처치 화학요법이 필요 없는 치료법 등 혁신적인 접근법 개발에 주력하고 있습니다. 화학요법 없는 전처치 치료는 세포 치료제 투여 전 환자의 면역체계를 억제하는 강력한 전처치 화학요법이 필요 없어 독성과 부작용을 줄일 수 있습니다. 예를 들어, 2024년 11월, 미국에 본사를 둔 임상 단계의 바이오 제약 기업 Fate Therapeutics Inc.는 기성품 CD19 표적 CAR NK 세포 치료제인 FT522를 발표하였습니다. 이 치료법은 동종 면역 방어 수용체 기술을 통합하여 CAR NK 세포가 지속적으로 존재하고 재발성 또는 난치성 B세포 림프종 및 자가면역질환 환자에서 병원성 B세포를 선택적으로 표적화할 수 있도록 합니다. 초기 단계의 임상시험에서 강력한 면역 억제 없이도 유망한 안전성과 유효성을 보여주었습니다.
목차
제1장 주요 요약
제2장 시장 특징
제3장 시장 공급망 분석
제4장 세계 시장 동향과 전략
제5장 최종 이용 산업 시장 분석
제6장 시장 : 금리, 인플레이션, 지정학, 무역 전쟁과 관세의 영향, 관세 전쟁과 무역 보호주의가 공급망에 미치는 영향, 코로나가 시장에 미치는 영향을 포함한 거시경제 시나리오
제7장 세계의 전략 분석 프레임워크, 현재 시장 규모, 시장 비교 및 성장률 분석
제8장 시장에서 세계의 총 잠재 시장 규모(TAM)
제9장 시장 세분화
제10장 지역별, 국가별 분석
제11장 아시아태평양 시장
제12장 중국 시장
제13장 인도 시장
제14장 일본 시장
제15장 호주 시장
제16장 인도네시아 시장
제17장 한국 시장
제18장 대만 시장
제19장 동남아시아 시장
제20장 서유럽 시장
제21장 영국 시장
제22장 독일 시장
제23장 프랑스 시장
제24장 이탈리아 시장
제25장 스페인 시장
제26장 동유럽 시장
제27장 러시아 시장
제28장 북미 시장
제29장 미국 시장
제30장 캐나다 시장
제31장 남미 시장
제32장 브라질 시장
제33장 중동 시장
제34장 아프리카 시장
제35장 시장 규제 상황과 투자 환경
제36장 경쟁 구도와 기업 개요
제37장 기타 주요 기업과 혁신적 기업
제38장 세계의 시장 경쟁 벤치마킹과 대시보드
제39장 주요 인수합병
제40장 시장 잠재력이 높은 국가, 부문, 전략
제41장 부록
KSM
영문 목차
영문목차
Chimeric antigen receptor-natural killer (CAR-NK) cell therapy is an advanced immunotherapy that genetically modifies natural killer (NK) cells with chimeric antigen receptors (CARs) to enhance their ability to recognize and destroy cancer cells. It is used for treating hematologic malignancies, solid tumors, and certain viral infections, offering advantages such as a lower risk of cytokine release syndrome (CRS), reduced potential for graft-versus-host disease (GvHD), and suitability for allogeneic (off-the-shelf) applications.
The main types of CAR-NK cell therapy include cytokine therapy, adoptive NK cell therapy, genetically engineered NK cell therapy, and others. Cytokine therapy involves the use of signaling proteins, such as interferons or interleukins, to modulate the immune system-either to stimulate anti-tumor activity or suppress harmful inflammation in autoimmune conditions. The various cell sources include peripheral blood-derived NK cells, cord blood-derived NK cells, induced pluripotent stem cell (iPSC)-derived NK cells, and NK cell lines. These therapies are applied in areas such as solid tumors, hematologic malignancies, and others, and are utilized by end users including hospitals, cancer research institutes, and biotechnology and pharmaceutical companies.
Tariffs have impacted the CAR-NK cell therapy market by increasing the cost of imported laboratory equipment, gene-editing tools, and cell culture reagents, which has disrupted the supply chain and slowed therapy production. Segments like genetically engineered NK cell therapies and cytokine-modified therapies are most affected, particularly in North America and Europe, which rely on imports for specialized materials. On the positive side, tariffs have encouraged local manufacturing, investment in domestic biomanufacturing facilities, and innovation in cost-efficient CAR-NK cell therapy solutions.
The chimeric antigen receptor-natural killer (car-nk) cell therapy market research report is one of a series of new reports from The Business Research Company that provides chimeric antigen receptor-natural killer (car-nk) cell therapy market statistics, including chimeric antigen receptor-natural killer (car-nk) cell therapy industry global market size, regional shares, competitors with a chimeric antigen receptor-natural killer (car-nk) cell therapy market share, detailed chimeric antigen receptor-natural killer (car-nk) cell therapy market segments, market trends and opportunities, and any further data you may need to thrive in the chimeric antigen receptor-natural killer (car-nk) cell therapy industry. This chimeric antigen receptor-natural killer (car-nk) cell therapy market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The chimeric antigen receptor-natural killer (car-nk) cell therapy market size has grown strongly in recent years. It will grow from $2.42 billion in 2025 to $2.58 billion in 2026 at a compound annual growth rate (CAGR) of 6.6%. The growth in the historic period can be attributed to limited availability of car-nk therapies, reliance on autologous nk cell therapy, growing incidence of hematologic cancers, increasing oncology research activities, regulatory approvals for early-generation nk cell therapies.
The chimeric antigen receptor-natural killer (car-nk) cell therapy market size is expected to see strong growth in the next few years. It will grow to $3.28 billion in 2030 at a compound annual growth rate (CAGR) of 6.2%. The growth in the forecast period can be attributed to development of genetically engineered car-nk cells, expansion of off-the-shelf therapies, rising adoption of cytokine and t cell receptor modified nk cells, increasing funding for clinical trials, integration of ai and big data in therapy optimization. Major trends in the forecast period include growth in allogeneic (off-the-shelf) car-nk cell therapies, expansion of hematological malignancy and solid tumor applications, integration of gene editing and cytokine gene modification techniques, increasing adoption of combination and immune checkpoint therapies, rising investment in clinical trials and oncology research programs.
The rising incidence of cancer worldwide is expected to drive the growth of the chimeric antigen receptor-natural killer (CAR-NK) cell therapy market in the coming years. Cancer encompasses a group of diseases characterized by the uncontrolled proliferation and spread of abnormal cells that can invade and damage body tissues. The rising incidence of cancer is attributed to factors such as aging populations and unhealthy lifestyles, as older age increases the accumulation of mutations over time, and habits like smoking, poor diet, and physical inactivity elevate cancer risk. CAR-NK cell therapy supports cancer treatment by engineering natural killer cells to specifically recognize and eliminate cancer cells, enhancing the immune system's targeted attack on tumors. For instance, in February 2024, the World Health Organization (WHO), a Switzerland-based intergovernmental organization, estimated that the 20 million new cancer cases reported in 2022 are projected to increase by 77% to over 35 million cases by 2050. Therefore, the rising incidence of cancer worldwide is propelling the growth of the CAR-NK cell therapy market.
Major companies in the CAR-NK cell therapy market are focusing on developing innovative approaches such as conditioning chemotherapy-free treatments to create safer and more effective off-the-shelf cellular therapies. Conditioning chemotherapy-free treatment eliminates the need for intensive pre-treatment chemotherapy to suppress the patient's immune system before administering cellular therapies, thereby reducing toxicity and adverse effects. For example, in November 2024, Fate Therapeutics Inc., a US-based clinical-stage biopharmaceutical company, launched FT522, an off-the-shelf CD19-targeted CAR NK cell therapy. This therapy integrates alloimmune defense receptor technology, allowing CAR NK cells to persist and selectively target pathogenic B cells in patients with relapsed or refractory B-cell lymphoma and autoimmune diseases, demonstrating promising safety and efficacy in early-phase clinical trials without requiring intensive immune suppression.
In April 2023, NKGen Biotech, a US-based biopharmaceutical company, merged with Graf Acquisition Corp. IV to become a publicly listed entity and advance its clinical development programs. Through this merger, NKGen Biotech aims to secure funding, leverage the combined expertise and resources of both organizations, accelerate innovation, expand its therapeutic pipeline, and bring transformative treatments for neurodegenerative and autoimmune diseases to patients more efficiently. Graf Acquisition Corp. IV is a US-based publicly listed special purpose acquisition company (SPAC) focused on partnering with growth-stage life sciences companies.
Major companies operating in the chimeric antigen receptor-natural killer (car-nk) cell therapy market are Artiva Biotherapeutics Inc., Nkarta Inc., Fate Therapeutics Inc., Acepodia Inc., Cartherics Inc., Century Therapeutics Inc., Catamaran Bio Inc., Glycostem Therapeutics Ltd., ImmuneBridge Co. Ltd., ONK Therapeutics Inc., Senti Biosciences Inc., Wugen Therapeutics Inc., Chimeric Therapeutics Limited, Nuwacell Biotechnologies Co. Ltd., Nkarta Therapeutics Inc., GICELL Co. Ltd.
North America was the largest region in the chimeric antigen receptor-natural killer (CAR-NK) cell therapy market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the chimeric antigen receptor-natural killer (car-nk) cell therapy market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
The countries covered in the chimeric antigen receptor-natural killer (car-nk) cell therapy market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The chimeric antigen receptor-natural killer (CAR-NK) cell therapy market includes revenues earned by entities through the research and development, clinical trial management, cell manufacturing, personalized treatment planning, and post-therapy patient monitoring. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Chimeric Antigen Receptor-Natural Killer (CAR-NK) Cell Therapy Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses chimeric antigen receptor-natural killer (car-nk) cell therapy market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase
Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on end user analysis.
Benchmark performance against key competitors based on market share, innovation, and brand strength.
Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.
Where is the largest and fastest growing market for chimeric antigen receptor-natural killer (car-nk) cell therapy ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The chimeric antigen receptor-natural killer (car-nk) cell therapy market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.
Scope
Markets Covered:1) By Type: Adoptive Natural Killer (NK) Cell Therapy; Genetically Engineered Natural Killer Cell Therapy; Other Types
Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: Word, PDF or Interactive Report
+ Excel Dashboard
Added Benefits
Bi-Annual Data Update
Customisation
Expert Consultant Support
Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.
4.1.5 Internet Of Things (Iot), Smart Infrastructure & Connected Ecosystems
4.2. Major Trends
4.2.1 Growth In Allogeneic (Off-The-Shelf) Car-Nk Cell Therapies
4.2.2 Expansion Of Hematological Malignancy And Solid Tumor Applications
4.2.3 Integration Of Gene Editing And Cytokine Gene Modification Techniques
4.2.4 Increasing Adoption Of Combination And Immune Checkpoint Therapies
4.2.5 Rising Investment In Clinical Trials And Oncology Research Programs
5. Chimeric Antigen Receptor-Natural Killer (CAR-NK) Cell Therapy Market Analysis Of End Use Industries
5.1 Hospitals
5.2 Cancer Research Institutes
5.3 Biotechnology Companies
5.4 Pharmaceutical Companies
5.5 Academic And Clinical Research Centers
6. Chimeric Antigen Receptor-Natural Killer (CAR-NK) Cell Therapy Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, Supply Chain Impact from Tariff War & Trade Protectionism, And Covid And Recovery On The Market
7. Global Chimeric Antigen Receptor-Natural Killer (CAR-NK) Cell Therapy Strategic Analysis Framework, Current Market Size, Market Comparisons And Growth Rate Analysis
7.1. Global Chimeric Antigen Receptor-Natural Killer (CAR-NK) Cell Therapy PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
7.2. Global Chimeric Antigen Receptor-Natural Killer (CAR-NK) Cell Therapy Market Size, Comparisons And Growth Rate Analysis
7.3. Global Chimeric Antigen Receptor-Natural Killer (CAR-NK) Cell Therapy Historic Market Size and Growth, 2020 - 2025, Value ($ Billion)
7.4. Global Chimeric Antigen Receptor-Natural Killer (CAR-NK) Cell Therapy Forecast Market Size and Growth, 2025 - 2030, 2035F, Value ($ Billion)
8. Global Chimeric Antigen Receptor-Natural Killer (CAR-NK) Cell Therapy Total Addressable Market (TAM) Analysis for the Market
8.1. Definition and Scope of Total Addressable Market (TAM)
8.2. Methodology and Assumptions
8.3. Global Total Addressable Market (TAM) Estimation
8.4. TAM vs. Current Market Size Analysis
8.5. Strategic Insights and Growth Opportunities from TAM Analysis
9.7. Global Chimeric Antigen Receptor-Natural Killer (CAR-NK) Cell Therapy Market, Sub-Segmentation Of Other Types, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
14.2. Japan Chimeric Antigen Receptor-Natural Killer (CAR-NK) Cell Therapy Market, Segmentation By Type, Segmentation By Cell Source, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
15. Australia Chimeric Antigen Receptor-Natural Killer (CAR-NK) Cell Therapy Market
15.1. Australia Chimeric Antigen Receptor-Natural Killer (CAR-NK) Cell Therapy Market, Segmentation By Type, Segmentation By Cell Source, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
16. Indonesia Chimeric Antigen Receptor-Natural Killer (CAR-NK) Cell Therapy Market
16.1. Indonesia Chimeric Antigen Receptor-Natural Killer (CAR-NK) Cell Therapy Market, Segmentation By Type, Segmentation By Cell Source, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
17. South Korea Chimeric Antigen Receptor-Natural Killer (CAR-NK) Cell Therapy Market
17.1. South Korea Chimeric Antigen Receptor-Natural Killer (CAR-NK) Cell Therapy Market Overview
Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
17.2. South Korea Chimeric Antigen Receptor-Natural Killer (CAR-NK) Cell Therapy Market, Segmentation By Type, Segmentation By Cell Source, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
18.2. Taiwan Chimeric Antigen Receptor-Natural Killer (CAR-NK) Cell Therapy Market, Segmentation By Type, Segmentation By Cell Source, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
19. South East Asia Chimeric Antigen Receptor-Natural Killer (CAR-NK) Cell Therapy Market
19.1. South East Asia Chimeric Antigen Receptor-Natural Killer (CAR-NK) Cell Therapy Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
19.2. South East Asia Chimeric Antigen Receptor-Natural Killer (CAR-NK) Cell Therapy Market, Segmentation By Type, Segmentation By Cell Source, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
20. Western Europe Chimeric Antigen Receptor-Natural Killer (CAR-NK) Cell Therapy Market
20.1. Western Europe Chimeric Antigen Receptor-Natural Killer (CAR-NK) Cell Therapy Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
20.2. Western Europe Chimeric Antigen Receptor-Natural Killer (CAR-NK) Cell Therapy Market, Segmentation By Type, Segmentation By Cell Source, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
21. UK Chimeric Antigen Receptor-Natural Killer (CAR-NK) Cell Therapy Market
21.1. UK Chimeric Antigen Receptor-Natural Killer (CAR-NK) Cell Therapy Market, Segmentation By Type, Segmentation By Cell Source, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
26.2. Eastern Europe Chimeric Antigen Receptor-Natural Killer (CAR-NK) Cell Therapy Market, Segmentation By Type, Segmentation By Cell Source, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
27. Russia Chimeric Antigen Receptor-Natural Killer (CAR-NK) Cell Therapy Market
27.1. Russia Chimeric Antigen Receptor-Natural Killer (CAR-NK) Cell Therapy Market, Segmentation By Type, Segmentation By Cell Source, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
28. North America Chimeric Antigen Receptor-Natural Killer (CAR-NK) Cell Therapy Market
28.1. North America Chimeric Antigen Receptor-Natural Killer (CAR-NK) Cell Therapy Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
28.2. North America Chimeric Antigen Receptor-Natural Killer (CAR-NK) Cell Therapy Market, Segmentation By Type, Segmentation By Cell Source, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
29. USA Chimeric Antigen Receptor-Natural Killer (CAR-NK) Cell Therapy Market
Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
30.2. Canada Chimeric Antigen Receptor-Natural Killer (CAR-NK) Cell Therapy Market, Segmentation By Type, Segmentation By Cell Source, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
31. South America Chimeric Antigen Receptor-Natural Killer (CAR-NK) Cell Therapy Market
31.1. South America Chimeric Antigen Receptor-Natural Killer (CAR-NK) Cell Therapy Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
31.2. South America Chimeric Antigen Receptor-Natural Killer (CAR-NK) Cell Therapy Market, Segmentation By Type, Segmentation By Cell Source, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
32. Brazil Chimeric Antigen Receptor-Natural Killer (CAR-NK) Cell Therapy Market
32.1. Brazil Chimeric Antigen Receptor-Natural Killer (CAR-NK) Cell Therapy Market, Segmentation By Type, Segmentation By Cell Source, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
